Effect of metabolic syndrome on survival outcome of chronic kidney disease

doi:10.3969/j.issn.1006-7795.2021.04.016

Abstract

Abstract: Objective To investigate the the effect of metabolic syndrome (MS) on survival outcomes in patients with chronic kidney disease (CKD) stage 1-5. Methods The patients with CKD from January 2006 to September 2008 in the Department of Nephrology of Peking University Third Hospital were enrolled as the subjects of study. General data and laboratory results of all subjects were collected. The follow-up ended on December 31, 2016, with the all-cause death as the end point event. Kaplan-Meier method and Cox regression analysis were used to screen out independent risk factors for CKD survival outcome. Results A total of 881 survival patients with CKD stage 1-5 were enrolled and completed the follow-up, including 307 with MS and 574 without MS. Totally 82 patients died at the end point of follow-up. Survival analysis showed that age ≥65 years old, serum albumin＜42 g/L, MS and cardiovascular and cerebrovascular diseases were independent risk factors for survival prognosis of CKD patients(P<0.05). Conclusions Metabolic syndrome is an independent risk factor for survival outcomes of CKD 1-5 patients, and the risk of death of CKD stage 1-5 patients with MS is increased.

Key words: metabolic syndrome, chronic kidney disease, survival prognosis, risk factors

CLC Number:

Lai Xuan, Zhang Aihua. Effect of metabolic syndrome on survival outcome of chronic kidney disease[J]. Journal of Capital Medical University, 2021, 42(4): 609-614.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2021.04.016

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2021/V42/I4/609

References

[1] Tozawa M, Iseki C, Tokashiki K, et al. Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults[J]. Hypertens Res,2007,30(10):937-943.
[2] Navaneethan S D, Schold J D, Kirwan J P, et al. Metabolic syndrome, ESRD, and death in CKD[J]. Clin J Am Soc Nephrol,2013,8(6):945-952.
[3] 中华医学会糖尿病学分会代谢综合征研究协作组. 中华医学会糖尿病学分会关于代谢综合征的建议[J]. 中华糖尿病杂志,2004,12(3):156-161.
[4] Bakhshayeshkaram M, Roozbeh J, Heidari S T, et al. Relationships between various components of metabolic syndrome and chronic kidney disease in Shiraz, Iran[J]. Int J Endocrinol Metab,2019,17(2):e81822.
[5] Wu N, Qin Y, Chen S, et al. Association between metabolic syndrome and incident chronic kidney disease among Chinese: a nation-wide cohort study and updated meta-analysis[J]. Diabetes Metab Res Rev,2021,online ahead of print.
[6] Chen J, Kong X, Jia X, et al. Association between metabolic syndrome and chronic kidney disease in a Chinese urban population[J]. Clin Chim Acta,2017,470:103-108.
[7] Thomas G N, Schooling C M, Mcghee S M, et al. Metabolic syndrome increases all-cause and vascular mortality: the Hong Kong Cardiovascular Risk Factor Study[J]. Clin Endocrinol (Oxf),2007,66(5):666-671.
[8] Mancia G, Bombelli M, Facchetti R, et al. Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population[J]. J Hypertens,2008,26(8):1602-1611.
[9] Kibria G M A, Crispen R. Prevalence and trends of chronic kidney disease and its risk factors among US adults: an analysis of NHANES 2003-18[J]. Prev Med Rep,2020,20:101193.
[10] 张丰萍,冯胜,石永兵. 代谢综合征与腹膜透析患者预后的关系[J]. 肾脏病与透析肾移植杂志,2012,21(5):435-438.
[11] Vogt B P, Souza P L, Minicucci M F, et al. Metabolic syndrome criteria as predictors of insulin resistance, inflammation and mortality in chronic hemodialysis patients[J]. Metab Syndr Relat Disord,2014,12(8):443-449.
[12] Rhee C M, Ahmadi S F, Kalantar-Zadeh K. The dual roles of obesity in chronic kidney disease: a review of the current literature[J]. Curr Opin Nephrol Hypertens,2016,25(3):208-216.
[13] Do Sameiro M-Faria, Ribeiro S, Costa E, et al. Risk factors for mortality in hemodialysis patients: two-year follow-up study[J]. Dis Markers,2013,35(6):791-798.
[14] Chiu H, Wu P Y, Huang J C, et al. There is a U shaped association between non high density lipoprotein cholesterol with overall and cardiovascular mortality in chronic kidney disease stage 3-5[J]. Sci Rep,2020,10(1):12749.
[15] Silbernagel G, Genser B, Drechsler C, et al. HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patients[J].J Am Soc Nephrol,2015,26(2):484-492.
[16] Holzer M, Birner-Gruenberger R, Stojakovic T, et al. Uremia alters HDL composition and function[J] J Am Soc Nephrol,2011,22(9):1631-1641.
[17] Marques G L, Hayashi S, Bjällmark A, et al. Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3-5[J]. Sci Rep,2021,11(1):2473.
[18] Jagadeswaran D, Indhumathi E, Hemamalini A J, et al. Inflammation and nutritional status assessment by malnutrition inflammation score and its outcome in pre-dialysis chronic kidney disease patients[J] Clin Nutr,2019,38(1):341-347.